Prime Medicine
Cambridge, United States · Biotechnology, Genetics, Health Care
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right p
Key facts
- Headquarters
- Cambridge, United States
- Employees
- 205
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (PRME)
- Website
- primemedicine.com
- Company page
Recent activity at Prime Medicine
- : SEC 8-K (1.01): On November 10, 2026, Prime Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Goldman Sachs & Co. LLC for an underwritten public offering of 35,714,286 shares of the Company's common stock at a price of $3.50 per share. The underwriters have an option to purchase an additional 5,357,142 shares within 30 days. The net proceeds from the offering are estimated to be approximately $134.7 million, which will support their Wilson disease and alpha-1 antitrypsin deficiency programs along with general corporate purposes. The offering is expected to close on or about November 12, 2026, pending customary closing conditions.
- : SEC 8-K (8.01): On November 10, 2026, Prime Medicine, Inc. posted an updated corporate presentation on its investor relations website. This presentation includes preliminary unaudited estimates of its cash, cash equivalents, and short-term investments as of September 30, 2026. The filing, categorized under Item 8.01 for other events, emphasizes that forward-looking statements contained within are subject to changes and uncertainties and should not be relied upon beyond the date of the report. The complete presentation is attached as Exhibit 99.1 to the report.
- : SEC 8-K (8.01): On July 6, 2026, Prime Medicine, Inc. received a final arbitration award from the arbitration tribunal related to their 2019 Collaboration and License Agreement with Beam Therapeutics, Inc. The Tribunal ruled that the development candidate PM647 is within Prime Medicine's defined 'Field', confirming that they did not breach the Agreement. This decision denied Beam's claims for damages and injunctive relief against Prime. The outcome has significant implications for the ongoing collaboration and future developments in treatments for Alpha-1 Antitrypsin Deficiency (AATD).
- : Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On March 3, 2026, Prime Medicine, Inc. posted an updated corporate presentation on its website, which is accessible at https://investors.primemedicine.com/news-events. This presentation is furnished as Exhibit 99.2 to the current report and is intended to provide updated information for investors. The corporate presentation outlines recent developments and strategic initiatives pertinent to the company's operations but is for informational purposes only and does not constitute a formal filing under the Exchange Act. No specific financial amounts are mentioned, and the presentation's disclosure is part of the company's broader communication strategy to keep shareholders informed.
- : SEC 8-K (7.01): On January 12, 2026, Prime Medicine, Inc. released an updated corporate presentation on its website to provide enhanced information for investors and stakeholders. This presentation is made available for review at https://investors.primemedicine.com/news-events. While the presentation contains important business updates, it is noted that the information is purely for reference and is not formally incorporated into the Current Report under the Securities Exchange Act. The update aims to provide greater clarity on the company's strategic direction and operational insights.
- : SEC 8-K (7.01): On January 12, 2026, Prime Medicine, Inc. updated its corporate presentation and posted it on its website for investors. The presentation is furnished as Exhibit 99.1 of the Form 8-K, highlighting the company's latest developments and strategic initiatives. This reflects the company's ongoing efforts to communicate with its shareholders and provide important information regarding its operations and future direction. The corporate presentation aims to enhance transparency and engagement with security holders, as it serves as a critical tool for investor relations.
- : Prime Medicine Appoints Matthew Hawryluk as Chief Business Officer
- : Cystic Fibrosis Foundation invests up to $24 million in Prime Medicine to advance gene editing therapy for cystic fibrosis.
Prime Medicine funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Funding Round | $24.0M |
Leadership
- Steve Engen, Advisor
- Svetlana Makhni, Chief Financial Officer
- Matthew Hawryluk, Chief Business Officer
- Allan Reine, Chief Executive Officer
Verified email and direct lines for Prime Medicine’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Prime Medicine files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Prime Medicine in the news
- Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates - GlobeNewswire (Mar 03, 2026)
- Prime Medicine Doses First Patient in Global Phase 1/2 Trial of PM577a for Wilson Disease and Receives FDA Rare Pediatric Disease Designation | PRME Stock News - Quiver Quantitative (Oct 05, 2026)
- A Wilson disease gene-editing trial has dosed its first patient. Initial data are expected in 2027. - Stock Titan (Nov 12, 2026)
- Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewswire (Jun 03, 2026)
- Company: Prime Medicine - CRISPR Medicine News (Oct 15, 2021)
- Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire (Sep 03, 2026)
- Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire (May 07, 2026)
- Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire (Nov 12, 2026)
Companies similar to Prime Medicine
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Rocket Pharmaceuticals · Biotechnology, Genetics, Health Care, Therapeutics
- Genethon · Biotechnology, Genetics, Health Care, Therapeutics
- Precision BioSciences · Biotechnology, Genetics, Health Care, Therapeutics
- Sangamo Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
About Prime Medicine: questions and answers
What does Prime Medicine do?
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right p
Where is Prime Medicine headquartered?
Prime Medicine is headquartered in Cambridge, United States.
How many employees does Prime Medicine have?
Prime Medicine has about 205 employees.
Has Prime Medicine raised funding?
Yes. Fundz has recorded 1 funding event for Prime Medicine. The most recent, Funding Round of $24.0M, was in Jul 2025.
Who leads Prime Medicine?
Allan Reine is a Chief Executive Officer at Prime Medicine.
What is the latest news on Prime Medicine?
On Nov 12, 2026, SEC 8-K (1.01): On November 10, 2026, Prime Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Goldman Sachs & Co. LLC for an underwritten public offering of 35,714,286 shares of the Company's common stock at a price of $3.50 per share. The underwr
Is Prime Medicine a public company?
Yes. Prime Medicine is publicly traded under the ticker PRME.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy